Inhalation Sciences receives new Contract Research order from global corporation based in Europe
December 19, Stockholm, Sweden. The order, worth 0.25 MSEK, follows a successful earlier collaboration. ISAB CEO Lena Heffler: “Customers as large and innovative as this one returning to carry out more projects shows clearly how outstanding our data is, and the control and precision it delivers.”
This order is the result of a successful, earlier research collaboration that delivered important data to the customer's development project. The Contract Research will be carried out using PreciseInhale, ISAB’s advanced R&D aerosol lab system.
Precision dosing: controlled aerosol, controlled outcomes
Uniquely, PreciseInhale generates aerosols in precise, controllable doses, producing exceptionally accurate—and repeatable—data. The precision dosing methodology gives inhalation scientists outstanding control of their aerosols, delivering data that eliminates errors in early-stage research, and significantly reduces the development time and cost of development of new inhaled therapies.
For more information about Inhalation Sciences please contact: Lena Heffler, CEO Email: firstname.lastname@example.org Phone: +46 (0)70 205 96 20Press release in PDF format